Guselkumab for Psoriasis in Patients With Active or Prior Malignancy: A Multicentre Retrospective Study

IF 1.8 4区医学 Q2 DERMATOLOGY

Australasian Journal of Dermatology Pub Date : 2025-07-15 DOI:10.1111/ajd.14573

Francisco Javier Melgosa Ramos, Sergio Santos Alarcón, Almudena Mateu Puchades, Isabel Belinchón Romero, Gemma Mª. Pérez Pastor, Luca Schneller-Pavelescu Apetrei, Francisco Javier Mataix Díaz, Antonio Martorell, Manel Velasco Pastor, José María Ortíz Salvador, Antonio Sahuquillo Torralba, Marta Galarreta Pascual, Jorge Magdaleno Tapial

{"title":"Guselkumab for Psoriasis in Patients With Active or Prior Malignancy: A Multicentre Retrospective Study","authors":"Francisco Javier Melgosa Ramos, Sergio Santos Alarcón, Almudena Mateu Puchades, Isabel Belinchón Romero, Gemma Mª. Pérez Pastor, Luca Schneller-Pavelescu Apetrei, Francisco Javier Mataix Díaz, Antonio Martorell, Manel Velasco Pastor, José María Ortíz Salvador, Antonio Sahuquillo Torralba, Marta Galarreta Pascual, Jorge Magdaleno Tapial","doi":"10.1111/ajd.14573","DOIUrl":null,"url":null,"abstract":"<div>\n \n <p>Managing moderate-to-severe psoriasis in patients with current or past malignancy remains a therapeutic challenge. We conducted a multicentre, retrospective real-world study to assess the safety and effectiveness of guselkumab in this complex population. Thirty patients were included, of whom 11 had active cancer at the time of guselkumab initiation. After 52 weeks of follow-up, guselkumab achieved sustained clinical improvement in skin and joint symptoms, with no observed cases of cancer progression or recurrence. Two patients developed new malignancies during treatment, but guselkumab was not discontinued. These findings support the use of IL-23 inhibitors as a safe therapeutic option in this complex patient population.</p>\n </div>","PeriodicalId":8638,"journal":{"name":"Australasian Journal of Dermatology","volume":"66 6","pages":"359-363"},"PeriodicalIF":1.8000,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Australasian Journal of Dermatology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/ajd.14573","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"DERMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Managing moderate-to-severe psoriasis in patients with current or past malignancy remains a therapeutic challenge. We conducted a multicentre, retrospective real-world study to assess the safety and effectiveness of guselkumab in this complex population. Thirty patients were included, of whom 11 had active cancer at the time of guselkumab initiation. After 52 weeks of follow-up, guselkumab achieved sustained clinical improvement in skin and joint symptoms, with no observed cases of cancer progression or recurrence. Two patients developed new malignancies during treatment, but guselkumab was not discontinued. These findings support the use of IL-23 inhibitors as a safe therapeutic option in this complex patient population.

查看原文本刊更多论文

Guselkumab治疗银屑病活动性或既往恶性肿瘤患者：一项多中心回顾性研究

管理中度至重度牛皮癣患者目前或过去的恶性肿瘤仍然是一个治疗挑战。我们进行了一项多中心、回顾性现实世界研究，以评估guselkumab在这一复杂人群中的安全性和有效性。纳入30例患者，其中11例在guselkumab开始时患有活动性癌症。经过52周的随访，guselkumab在皮肤和关节症状方面取得了持续的临床改善，没有观察到癌症进展或复发的病例。两名患者在治疗期间出现了新的恶性肿瘤，但并没有停药。这些发现支持在这种复杂的患者群体中使用IL-23抑制剂作为安全的治疗选择。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Australasian Journal of Dermatology 医学-皮肤病学

CiteScore

3.20

自引率

5.00%

发文量

186

审稿时长

6-12 weeks

期刊介绍： Australasian Journal of Dermatology is the official journal of the Australasian College of Dermatologists and the New Zealand Dermatological Society, publishing peer-reviewed, original research articles, reviews and case reports dealing with all aspects of clinical practice and research in dermatology. Clinical presentations, medical and physical therapies and investigations, including dermatopathology and mycology, are covered. Short articles may be published under the headings ‘Signs, Syndromes and Diagnoses’, ‘Dermatopathology Presentation’, ‘Vignettes in Contact Dermatology’, ‘Surgery Corner’ or ‘Letters to the Editor’.